Results 271 to 280 of about 146,281 (306)

Venetoclax: Targeting BCL2 in Hematological Cancers

2018
Over the last years, targeted anti-cancer therapy with small-molecule inhibitors and antibodies moved to the forefront as a strategy to treat hematological cancers. These novel agents showed outstanding effects in treatment of patients, often irrespective of their underlying genetic features.
Annika, Scheffold, Billy Michael Chelliah, Jebaraj, Stephan, Stilgenbauer   +2 more
openaire   +2 more sources

Bcl2

2017
Marco Ruggiero, John W. Anderson
openaire   +2 more sources

Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

Cancer Cell, 2023
Eric Wang, Jose Mario Bello Pineda, Won Jun Kim   +2 more
exaly  

BCL2 FAMILY INHIBITORS

Leukemia Research, 2023
openaire   +1 more source

Bcl2

1998
Tak W. Mak, Josef Penninger, John Roder, Janet Rossant, Mary Saunders   +4 more
openaire   +1 more source

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

Lancet, The, 2000
Christoph Hoeller, Trevor Lucas
exaly  

The Bcl2 family: regulators of the cellular life-or-death switch

Nature Reviews Cancer, 2002
Suzanne Cory, Jerry Adams
exaly  

Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability

Cell, 2002
Hans Ragnar Widlund, Han-Fei Ding, Ian J Jackson   +2 more
exaly  

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

Cancer Cell, 2019
Xiaohong Zhao, Matthew A Lawlor, Michelle Wang   +2 more
exaly  

Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors

Cell, 1998
Xu Luo, Xiaodong Wang
exaly